The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Research-use-only status: what it means legally and practically — a second dataset

This is a generated summary. It shows the 9 most-liked posts from a topic of 126, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
SR
s.radichTL2 Moderator Solution16 Oct 2024#4

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

7 likes 21mo
SH
s.hartmannTL2 Moderator25 Oct 2024#8
k.kimani, post #6: This follows post #3 rather than contradicting it. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

28 likes in reply to #6 21mo
AZ
an.zamoraTL2 Moderator10 Nov 2024#17

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

33 likes 21mo
IB
i.bakkenTL2 Moderator14 Dec 2024#40

Worth separating two things that post #36 runs together.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

27 likes 19mo
SD
s.dziedzicTL2 Moderator29 Dec 2024#51

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

29 likes 19mo
BV
bias_varianceTL4Biostatistician10 Jan 2025#60
crossover_entry, post #12: Coming back to post #10, because the follow-up matters more than the original answer. Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness. Go to post

I read post #58 twice before replying, because I had assumed the opposite.

This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.

30 likes in reply to #12 19mo
AV
ai.vukovicTL2 Moderator22 Jan 2025#70

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

32 likes 18mo
EA
e.adeyemiTL2 Moderator24 Jan 2025#72

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

28 likes 18mo
TK
t.karlsenTL2 Moderator23 Feb 2025 · edited#97

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

28 likes 17mo

Read the full topic (126 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
KJMMYSDK+8 12 51k 7mo
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
LVAVHAPNV+77 82 12k 11mo
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…
TNDBSOLGHF+100 108 1.3k 8mo
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
KFKLVSHVAF+72 81 44k 1d
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
ARCDJBMRBR+40 44 2.8k 6mo

Related topics — sharing the tags research use only, mislabelling, needs a source

TopicParticipantsRepliesViewsActivity
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
CHDVRARZMD+76 82 52k 11mo
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. I would like to talk about documentation quality as a…
LSDBHK 2 1.8k 2mo
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…
BSHRTMNCI+20 24 18k 4mo
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…
SVTVMRZOIN+86 97 62k 8mo
Documenting a payment dispute without naming and shaming — the long version
Posting this under the heading it deserves: Documenting a payment dispute without naming and shaming — the long version Everything below is what sits behind that. I would like to talk about documentation…
MAQZIL 2 32k 1mo